Centroflora CMS (C² Pharma), a specialist in active pharmaceutical ingredients (APIs), has acquired manufacturing assets for a group of phytochemical APIs from German drugmaker Boehringer Ingelheim.

The Brazilian company also has signed a multi-year exclusive agreement with Boehringer to supply the market with phytochemical APIs. The acquired portfolio includes atropine and atropine sulfate, digoxin and digoxin micron, along with metildigoxin, homatropine methylbromide, homatropine hydrobromide and dihydroergotamine mesylate

Centroflora CMS will also distribute its own pilocarpine APIs, including pilocarpine hydrochloride and pilocarpine Nitrate, to more than 100 pharmaceutical companies in the US, Europe, South America, Asia, Africa and Australia.

Andrew Badrot, CEO of Centroflor, said the company plans to Immediately provide "a well-defined roadmap for the continuous supply ofphytochemical APIs to the marketplace."